BPIQ Pro/Elite/Apex Investor Posts

The 43rd Annual J.P. Morgan Health Care Conference is taking place in San Francisco, CA from January 13-16, 2025.

We’re always excited to find bio/pharma companies nearing their therapeutic product launch!

This post provides some ideas on how to Use BPIQ's Hedge Fund Data And Model Portfolios to Beat the Major Biotech ETFs.

TAKE HOME MESSAGE:

You can find updated Q3 bioHF holdings data at app.bpiq.com/hedgefunds

This weekend COGT reports some Big-Mover data on Bezuclastinib (CGT9486) at ASH.

SUMMARY

BACKGROUND

SUMMARY

At BPIQ, our goal is to help you make money investing in smid-cap biopharma stocks

See our post "Two Strategies to Make Money in a Biopharma Down Market" for key strategies to make money regardless of whether XBI is in an upward or downward trend

See our post "Two Strategies to Make Money in a Biopharma Down Market" for key strategies to make money regardless of whether XBI is in an upward or downward trend

At BPIQ, our goal is to help you make money investing in smid-cap biopharma stocks

In honor of the Obesity week conference, which starts tomorrow:

As a reminder, we are biopharma investors just like you. All of our Elite and Amp portfolios show percent holdings of real money accounts of our co-founder, Manny Vacchiano, JD, PhD. Thus, we are always looking to improve their performance and identify new strategies, including those that are more effective in this current down cycle for biopharma stocks.

As a reminder, we are biopharma investors just like you. All of our Elite and Amp portfolios show percent holdings of real money accounts of our co-founder, Manny Vacchiano, JD, PhD. Thus, we are always looking to improve their performance and identify new strategies, including those that are more effective in this current down cycle for biopharma stocks.

Repeating and expanding a bit on a post I just made in our discord chat here: One other comment re: $SRPT, I was looking at possible magnitude up and down on their upcoming big mover readout at end of year. On the one hand, they are already a $10B company so how much higher can they go? Well they have around $1B of annual revenue now, so they are trading at around 10x current revenue, which is not crazy. And if they get approval for all age groups, their addressable market fo

Valuable insights into ALDX

We have gone through the Q2 2023 financial reports to analysis each companies product revenue to see:

SUMMARY